Treatment of Renal Osteodystrophy with Hyperphosphatemia in CKD G3a–G5D
In patients with chronic kidney disease (CKD) stages G3a through G5D — including those on dialysis — the presence of progressively or persistently elevated serum phosphate (hyperphosphatemia) is the key trigger for active phosphate-lowering management in the context of renal osteodystrophy.
Clinical scenario
CKD G3a–G5D with
progressively or persistently elevated serum phosphate (hyperphosphatemia). Treatment decisions are based on this pattern of phosphate elevation — not on a single measurement.
Treatment Goals
- Lower elevated serum phosphate toward the normal range
- Avoid hypercalcemia in adult patients
Approach Overview
Management involves limiting dietary phosphate intake — taking into account the phosphate source — used alone or alongside pharmacological phosphate-binding therapy, with specific guidance applicable to adult patients.
References
DOI: 10.1038/ki.2009.191
- In patients with CKD G3a-G5D, decisions about phosphate-lowering treatment should be based on progressively or persistently elevated serum phosphate (Not Graded).
- In patients with CKD G3a–G5D, we suggest lowering elevated phosphate levels toward the normal range (2C).
- In patients with CKD G3a–G5D, we suggest limiting dietary phosphate intake in the treatment of hyperphosphatemia alone or in combination with other treatments (2D).
- It is reasonable to consider phosphate source (e.g., animal, vegetable, additives) in making dietary recommendations (Not Graded).
- In adult patients with CKD G3a–G5D, we suggest avoiding hypercalcemia (2C).
View source ↗